Encapsulated Ocular Cell Implant for Long-Term Retinal Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for vision-threatening disorders of the eye, such as glaucoma, retinitis pigmentosa, and age-related macular degeneration, face challenges in delivering therapeutic agents across the blood-retinal barrier and maintaining effective concentrations, while also requiring immunosuppression to prevent transplant rejection.

Innovation Solution

Implantation of a biocompatible capsule containing a cellular source of biologically active molecules, such as ARPE-19 cells, within the eye, surrounded by a semi-permeable membrane that allows diffusion of these molecules, providing therapeutic benefits for at least 12 months without the need for immunosuppression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If transplantation procedures are used to deliver therapeutic agents to the eye, then therapeutic benefit is achieved, but immunosuppression is required to prevent rejection

Engineering Contradiction:

Improvetherapeutic benefitVSAvoidimmunosuppression requirement

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the transplant system into two distinct components: (1) the cellular source of biologically active molecules, and (2) the biocompatible capsule with semi-permeable membrane that houses the cells. This segmentation allows the cells to be isolated from the host immune system while still delivering therapeutic molecules, thereby eliminating the need for immunosuppression while maintaining therapeutic benefit

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The biocompatible capsule with semi-permeable membrane acts as an intermediary between the transplanted cells and the host immune system. The membrane allows selective passage of molecules while blocking immune cells and antibodies, serving as a protective barrier that enables long-term cell survival and continuous therapeutic molecule delivery without immunosuppression

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If whole organs or tissues are transplanted to restore organ or tissue function, then dramatic benefits are achieved, but the number of suitable organs available is limited

Engineering Contradiction:

Improveorgan or tissue function restorationVSAvoidavailability of suitable organs

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention extracts only the essential functional component (cells that produce biologically active molecules) from whole organs or tissues, and encapsulates them in a biocompatible capsule. This extraction approach eliminates the need for whole organ transplantation while preserving the therapeutic function, thereby dramatically increasing the availability of suitable transplant material

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses local quality by selecting specific cell types that produce particular biologically active molecules needed for treating specific ocular conditions. Rather than transplanting entire organs, the capsule contains only the locally optimized cell population required to deliver the specific therapeutic effect needed

Inventive Principle:

Principle #3Local quality

3Reliability

If therapeutic agents are delivered into the eye to treat vision-threatening disorders, then treatment effectiveness is improved, but the blood-retinal barrier prevents maintaining effective concentrations

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidconcentration of therapeutic agent

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The encapsulated cells perform self-service by continuously producing and secreting biologically active molecules directly into the ocular environment. This localized production eliminates the need for repeated external administration and ensures continuous presence of therapeutic agents at effective concentrations, overcoming the blood-retinal barrier limitation

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The biocompatible capsule enables continuous delivery of biologically active molecules by housing living cells that continuously produce and secrete therapeutic agents. This continuous production and release mechanism maintains effective concentrations of therapeutic molecules in the eye over extended periods, unlike intermittent external administration

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method achieves long-term, therapeutically effective delivery of molecules like CNTF, improving visual acuity, retinal health, and reducing degeneration, while avoiding immunosuppression and transplant rejection.

Implementation Method 1

a semi-permeable membrane surrounding the core, wherein the membrane permits the diffusion of the biologically active molecule therethrough

Methodology Applied

Scientific EffectDiffusion: Diffusion

Data Source

PatentUS12485087B2Use of encapsulated cell therapy for treatment of ophthalmic disorders

Publication Date: 2025.12.02 NEUROTECH USA INC

AI summary

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.